


Synergistic effect of PRIMA-1Met (APR-246) and Azacitidine (AZA) in *TP53*-mutated myelodysplastic syndromes/acute myeloid leukemia cell lines



APR exhibits promising synergistic effects when combined with conventional AZA therapy in the high-risk subgroups of *TP53*-mutated MDS/AML